Australis Capital announced on 11 December 2019 that it has entered into an agreement with Folium Biosciences to merge into a combined company focused on non-psychoactive cannabinoid products. Existing Australis shareholders will own approximately 11% of the resulting company, but the plan is for Australis management to be involved in running the combined entity. We expect the company to divest its assets based in THC, with the goal of making the company fully federally legal in the US, and t
13 Dec 2019
Australis Capital - Australis to reverse merge with Folium
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Australis Capital - Australis to reverse merge with Folium
Australis Capital, Inc. (AUSAF:OTC) | 0 0 0.0%
- Published:
13 Dec 2019 -
Author:
Dr Nathaniel Calloway -
Pages:
5
Australis Capital announced on 11 December 2019 that it has entered into an agreement with Folium Biosciences to merge into a combined company focused on non-psychoactive cannabinoid products. Existing Australis shareholders will own approximately 11% of the resulting company, but the plan is for Australis management to be involved in running the combined entity. We expect the company to divest its assets based in THC, with the goal of making the company fully federally legal in the US, and t